Biotech Startups

MedGenome provides genetic and molecular diagnostic testing across areas including reproductive care, rare hereditary conditions, oncology, and infectious diseases, and operates a CAP-accredited multiomics laboratory with high-throughput sequencing and a proprietary analytics platform. It serves clinicians, hospitals, and pharma partners primarily across India and South Asia.

1 investor

Medipost is a biotechnology company focused on stem cell technology, including stem cell banking services and related research and development. It holds domestic and international patents and conducts government-funded research projects.

1 investor

Medic Life Sciences applies CRISPR functional genomics in 3D patient tumor-like cancer models to identify biomarkers, synthetic lethality, and resistance mutations for oncology drug development. The company focuses on discovering genetic features of cancer with translational relevance for stratifying patients and finding novel drug targets.

1 investor

MNS (Microneedle Solutions) develops medical technology based on microneedle systems, with stated aims of reducing health disparities and improving access to quality healthcare. The company originated from university research and works with advisors in RNA technologies and vaccines.

1 investor

Cannabis genomics company developing testing technologies to help growers, dispensaries, and labs ensure safe, quality cannabis.

1 investor

Medicinal Genomics provides microbial and plant testing solutions for the cannabis, nutraceutical, and food safety industries through validated qPCR assays and automated liquid handling platforms. Their offerings enable rapid pathogen detection and species identification with turnaround times measured in hours rather than days.

1 investor

MediciNova is a biopharmaceutical company that develops new drugs for diseases with limited or unestablished treatment options, aiming to serve patients with unmet medical needs. It focuses on discovering safe and effective medicines through drug discovery technology and collaborations with research institutions, medical institutions, and companies.

1 investor

Medikine engineers cytokine mimetics — peptide-based therapeutics that mimic natural cytokines — to treat serious diseases, with a focus on immuno-oncology. The company develops optimized therapies based on cytokine mimesis for clinical use.

1 investor

MediSieve develops a magnetic blood filtration system that uses nanoengineered magnetic particles and beads to remove pathogens such as harmful cells, bacteria, toxins, and inflammatory cytokines directly from a patient's bloodstream. The technology targets treatment for currently underserved patient groups.

1 investor

Medisix Therapeutics develops a pipeline of therapeutic products using integrated technology platforms spanning the product lifecycle, supported by a CMC platform for large-scale manufacturing.

1 investor

MediTrak provides a hypertension management solution for patients and healthcare providers. The company operates in the digital health space.

1 investor

BioResin develops bio-separation technology that upcycles agricultural byproducts such as acid whey, pea, and soy waste streams into edible "magnetic" fibers used to capture and purify proteins. Its products serve food and alternative-protein producers, including precision fermentation and plant-based applications, offering both a dual-upcycled fiber-protein hybrid ingredient and a food-grade high-purity processing aid.

1 investor

Medivant Healthcare manufactures sterile injectable medications for the pharmaceutical industry.

1 investor

Mednet provides a unified electronic clinical trial platform that enables sponsors, contract research organizations, and life sciences research organizations to design, build, and manage clinical studies. The company serves pharmaceutical, biotechnology, medical device, and academic institutions with eClinical technology and operational expertise across North America and globally.

1 investor

Meep develops biological monitoring technology to enable frequent clinical-grade testing for chronic disease patients, reducing unnecessary hospitalizations and intensive care admissions.

1 investor

Megakaryon is a regenerative medicine company that develops cell therapies, including iPS cell-derived products such as platelets, for clinical applications. The company operates through collaborative research partnerships with academic institutions and pharmaceutical manufacturers in Japan and internationally.

1 investor

Melior Discovery provides in vivo pharmacology services and phenotypic screening platforms for pharmaceutical and biopharmaceutical companies to evaluate candidate therapeutics in animal disease models. The company operates proprietary technology including theraTRACE® to identify new therapeutic potential and support drug development and repositioning.

1 investor

Melius MicroBiomics develops microbiome-based live biotherapeutics (its GEMM technology) to treat chronic inflammatory diseases, pursuing both human and animal health applications. The company's therapies originate from patented research at the University of British Columbia Okanagan's Gibson Lab.

1 investor

Melius Pharma is a drug development company that operates with part-time experts and external providers to conduct strategic and operational pharmaceutical development. The company focuses on formulation development and clinical advancement in the pharmaceutical sector.

1 investor

Boston-based developer of an in vitro diagnostic test for diabetes based on the glycated CD59 (GCD59) biomarker.

1 investor

Privately-held biotech company developing biologic therapies for retinal diseases

1 investor

1 investor

Mentari Therapeutics develops targeted biological therapies for migraine treatment, focusing on PACAP pathway inhibition through monoclonal and bispecific antibodies for patients with inadequate relief from existing anti-CGRP therapies.

1 investor

Merck is a science-led pharmaceutical company that develops medicines and vaccines for patients globally. The company focuses on innovation and long-term value creation through its research pipeline and commitment to healthcare advancement.

1 investor